Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction.
about
Cardiovascular prevention before admission reduces mortality following acute myocardial infarction in patients with diabetesDirect thrombin inhibitors as adjuncts to thrombolytic therapy.Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China.Hospital mortality of acute myocardial infarction in the thrombolytic era.Relevance of clinical trial results in myocardial infarction to medical practice: comparison of four year outcome in participants of a thrombolytic trial, patients receiving routine thrombolysis, and those deemed ineligible for thrombolysisChanging the site of delivery of thrombolytic treatment for acute myocardial infarction from the coronary care unit to the emergency department greatly reduces door to needle time.Prognostic implications of ventricular fibrillation in acute myocardial infarction: new strategies required for further mortality reduction.Interaction between arrival time and thrombolytic treatment in determining early outcome of acute myocardial infarction.Associations between ST depression, four year mortality, and in-hospital revascularisation in unselected patients with non-ST elevation acute coronary syndromes.Change in ST segment elevation 60 minutes after thrombolytic initiation predicts clinical outcome as accurately as later electrocardiographic changesThe effect of reduction of door-to-needle times on the administration of thrombolytic therapy for acute myocardial infarction.Thrombolytic treatment for myocardial infarction: an examination of practice in 39 United Kingdom hospitals. Myocardial Infarction Audit GroupInterventional management of acute myocardial infarction (AMI).Data on eligibility for thrombolytic treatment cannot be generalised.Opportunities for control of coronary heart disease in Australia.Thrombolytic eligibility.
P2860
Q28192788-C1A08B55-2E53-4F6B-BCE3-E2DD2D98D28FQ34027292-B1F764D9-9203-4E68-8288-E606E3C438B8Q34313975-AD5FEFC2-423B-4B5E-B2FC-A8BD3A3B4F8BQ35371836-F0AF545E-E6A6-4781-9E36-F4EDC8704E03Q35372488-54374F85-E929-44E8-88E9-DD7DA3710AC4Q35566966-03DCB339-87FB-4706-A6F9-FB0E9CDD565DQ35567017-2B8F4E5E-9382-4D22-B7E9-B0E26301E5A7Q35580681-47B1408C-9F8C-47A3-817B-FA8AAD038CB1Q35581080-C01504FC-2239-4A74-B9FE-FA28A7F48C6CQ35843040-833A8964-AAB3-414D-AC64-CF216FB74B27Q36613381-2E281054-DC11-496D-A461-9C36580955E2Q36846025-6D63BC6C-D96E-4D3A-928C-3E1D92CDE1ECQ41692791-FBB01A89-4F5C-48A3-B359-6F0DC8BB0425Q43190019-D737D090-6A5D-4736-85A4-02D6A0F791F4Q43571280-B0D3CA67-C399-4CCF-A344-D245ADBFE81EQ53736137-540D772E-F1D2-4523-A72F-395DC7BB26CC
P2860
Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Prospective evaluation of elig ...... n acute myocardial infarction.
@ast
Prospective evaluation of elig ...... n acute myocardial infarction.
@en
type
label
Prospective evaluation of elig ...... n acute myocardial infarction.
@ast
Prospective evaluation of elig ...... n acute myocardial infarction.
@en
prefLabel
Prospective evaluation of elig ...... n acute myocardial infarction.
@ast
Prospective evaluation of elig ...... n acute myocardial infarction.
@en
P2093
P2860
P1433
P1476
Prospective evaluation of elig ...... n acute myocardial infarction.
@en
P2093
Williams BF
Williams MG
P2860
P304
P356
10.1136/BMJ.312.7047.1637
P407
P577
1996-06-01T00:00:00Z